Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paracetamol + caffeine (Imexpharm)
- Development stage
- Unknown
- Lead developer
- Imexpharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Andol Fort is a combination analgesic and antipyretic medication manufactured by Imexpharm (IMP MMC). It consists of paracetamol (acetaminophen) and caffeine. Paracetamol is a non-aspirin analgesic that acts primarily in the central nervous system to inhibit prostaglandin synthesis, thereby reducing pain and fever. Caffeine is included as an adjuvant to enhance the analgesic effect of paracetamol, likely through its action as an adenosine receptor antagonist and its ability to improve the absorption or metabolic profile of the analgesic. Andol Fort is indicated for the symptomatic relief of mild to moderate pain, including headaches, migraines, toothaches, sore throats, and musculoskeletal pain, as well as for the reduction of fever associated with various conditions.
- Brand names
- Andol Fort
- Other names
- acetaminophen + caffeineParacetamol/Caffeine
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)
Beyond the preview
Go deeper on paracetamol + caffeine (Imexpharm).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paracetamol + caffeine (Imexpharm).